A Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories has a net margin of 20.64% compared to Agilent Technologies's net margin of -339.17%. Agilent Technologies's return on equity of 21.45% beat Bio-Rad Laboratories's return on equity of -9.62%.

Agilent Technologies has a consensus price target of $150.13, signalling upside risk potential of 1.88%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $404.33 which suggests that it could grow by 18.09%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.062, which suggesting that the stock is 6.243% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.115%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.65%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $649.7M. Agilent Technologies's net income of $351M is lower than Bio-Rad Laboratories's net income of $653.2M. Notably, Agilent Technologies's price-to-earnings ratio is 33.34x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.58x versus 3.77x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 20.64% compared to Agilent Technologies's net margin of 4.73%. Agilent Technologies's return on equity of 21.45% beat Bruker's return on equity of 19.61%.

Agilent Technologies has a consensus price target of $150.13, signalling upside risk potential of 1.88%. On the other hand Bruker has an analysts' consensus of $73.80 which suggests that it could grow by 29.75%. Given that Bruker has higher upside potential than Agilent Technologies, analysts believe Bruker is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.062, which suggesting that the stock is 6.243% more volatile than S&P 500. In comparison Bruker has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.959%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.65%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $864.4M. Agilent Technologies's net income of $351M is higher than Bruker's net income of $40.9M. Notably, Agilent Technologies's price-to-earnings ratio is 33.34x while Bruker's PE ratio is 27.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.58x versus 2.60x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 20.64% compared to Agilent Technologies's net margin of -21.86%. Agilent Technologies's return on equity of 21.45% beat Harvard Bioscience's return on equity of -20.42%.

Agilent Technologies has a consensus price target of $150.13, signalling upside risk potential of 1.88%. On the other hand Harvard Bioscience has an analysts' consensus of $6.25 which suggests that it could grow by 223.83%. Given that Harvard Bioscience has higher upside potential than Agilent Technologies, analysts believe Harvard Bioscience is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.062, which suggesting that the stock is 6.243% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.945%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.65%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $22M. Agilent Technologies's net income of $351M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Agilent Technologies's price-to-earnings ratio is 33.34x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.58x versus 0.85x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of 20.64% compared to Agilent Technologies's net margin of 13.8%. Agilent Technologies's return on equity of 21.45% beat Revvity's return on equity of 3.24%.

Agilent Technologies has a consensus price target of $150.13, signalling upside risk potential of 1.88%. On the other hand Revvity has an analysts' consensus of $137.14 which suggests that it could grow by 15.83%. Given that Revvity has higher upside potential than Agilent Technologies, analysts believe Revvity is more attractive than Agilent Technologies.

Agilent Technologies has a beta of 1.062, which suggesting that the stock is 6.243% more volatile than S&P 500. In comparison Revvity has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.677%.

Agilent Technologies has a quarterly dividend of $0.25 per share corresponding to a yield of 0.65%. Revvity offers a yield of 0.24% to investors and pays a quarterly dividend of $0.07 per share. Agilent Technologies pays 21.26% of its earnings as a dividend. Revvity pays out 5.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Agilent Technologies quarterly revenues are $1.7B, which are larger than Revvity quarterly revenues of $684M. Agilent Technologies's net income of $351M is higher than Revvity's net income of $94.4M. Notably, Agilent Technologies's price-to-earnings ratio is 33.34x while Revvity's PE ratio is 57.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agilent Technologies is 6.58x versus 5.37x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.